{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:14:56Z","timestamp":1791213296282,"version":"4.1.0"},"reference-count":26,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"12","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2023,4,20]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>\n                      Epcoritamab is a subcutaneously administered CD3xCD20 T-cell\u2013engaging, bispecific antibody that activates T cells, directing them to kill malignant CD20\n                      <jats:sup>+<\/jats:sup>\n                      B cells. Single-agent epcoritamab previously demonstrated potent antitumor activity in dose escalation across B-cell non-Hodgkin lymphoma subtypes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>\n                      In the dose-expansion cohort of a phase I\/II study (ClinicalTrials.gov identifier: NCT03625037 ), adults with relapsed or refractory CD20\n                      <jats:sup>+<\/jats:sup>\n                      large B-cell lymphoma and at least two prior therapy lines (including anti-CD20 therapies) received subcutaneous epcoritamab in 28-day cycles (once weekly step-up doses in weeks 1-3 of cycle 1, then full doses once weekly through cycle 3, once every 2 weeks in cycles 4-9, and once every 4 weeks in cycle 10 and thereafter) until disease progression or unacceptable toxicity. The primary end point was overall response rate by the independent review committee.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>As of January 31, 2022, 157 patients were treated (median age, 64 years [range, 20\u201083]; median of three [range, 2-11] prior therapy lines; primary refractory disease: 61.1%; prior chimeric antigen receptor (CAR) T-cell exposure: 38.9%). At a median follow-up of 10.7 months, the overall response rate was 63.1% (95% CI, 55.0 to 70.6) and the complete response rate was 38.9% (95% CI, 31.2 to 46.9). The median duration of response was 12.0 months (among complete responders: not reached). Overall and complete response rates were similar across key prespecified subgroups. The most common treatment-emergent adverse events were cytokine release syndrome (49.7%; grade 1 or 2: 47.1%; grade 3: 2.5%), pyrexia (23.6%), and fatigue (22.9%). Immune effector cell\u2013associated neurotoxicity syndrome occurred in 6.4% of patients with one fatal event.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Subcutaneous epcoritamab resulted in deep and durable responses and manageable safety in highly refractory patients with large B-cell lymphoma, including those with prior CAR T-cell exposure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.22.01725","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T16:00:28Z","timestamp":1671724828000},"page":"2238-2247","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":575,"title":["Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell\u2013Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial"],"prefix":"10.1200","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct03625037","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9941-2448","authenticated-orcid":false,"given":"Catherine","family":"Thieblemont","sequence":"first","affiliation":[{"name":"Assistance Publique & H\u00f4pitaux de Paris (APHP), H\u00f4pital Saint-Louis, H\u00e9mato-oncologie, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2143-9672","authenticated-orcid":false,"given":"Tycel","family":"Phillips","sequence":"additional","affiliation":[{"name":"University of Michigan Comprehensive Cancer Center, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3131-3718","authenticated-orcid":false,"given":"Herve","family":"Ghesquieres","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7988-1565","authenticated-orcid":false,"given":"Chan Y.","family":"Cheah","sequence":"additional","affiliation":[{"name":"Sir Charles Gairdner Hospital, Perth, Australia"},{"name":"Division of Internal Medicine, Medical School, University of Western Australia, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3218-3633","authenticated-orcid":false,"given":"Michael Roost","family":"Clausen","sequence":"additional","affiliation":[{"name":"Vejle Hospital, Vejle, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5158-1069","authenticated-orcid":false,"given":"David","family":"Cunningham","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Rok","family":"Do","sequence":"additional","affiliation":[{"name":"Keimyung University Dongsan Medical Center, Daegu, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Feldman","sequence":"additional","affiliation":[{"name":"Hackensack Meridian Health Hackensack University Medical Center, Hackensack, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1225-8757","authenticated-orcid":false,"given":"Robin","family":"Gasiorowski","sequence":"additional","affiliation":[{"name":"Concord Hospital, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[{"name":"MSC National Research Institute of Oncology, Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6145-4426","authenticated-orcid":false,"given":"Tae Min","family":"Kim","sequence":"additional","affiliation":[{"name":"Seoul National University Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5903-3788","authenticated-orcid":false,"given":"David John","family":"Lewis","sequence":"additional","affiliation":[{"name":"University Hospitals Plymouth NHS Trust, Derriford Hospital, Plymouth, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"van der Poel","sequence":"additional","affiliation":[{"name":"On behalf of the Lunenburg Lymphoma Phase I\/II Consortium-HOVON\/LLPC, Maastricht, Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Limei","family":"Poon","sequence":"additional","affiliation":[{"name":"National University Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Cota Stirner","sequence":"additional","affiliation":[{"name":"AbbVie, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurgul","family":"Kilavuz","sequence":"additional","affiliation":[{"name":"Genmab, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9744-991X","authenticated-orcid":false,"given":"Christopher","family":"Chiu","sequence":"additional","affiliation":[{"name":"Genmab, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghui","family":"Chen","sequence":"additional","affiliation":[{"name":"Genmab, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Sacchi","sequence":"additional","affiliation":[{"name":"Genmab, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Elliott","sequence":"additional","affiliation":[{"name":"Genmab, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahamtan","family":"Ahmadi","sequence":"additional","affiliation":[{"name":"Genmab, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3873-1741","authenticated-orcid":false,"given":"Martin","family":"Hutchings","sequence":"additional","affiliation":[{"name":"Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6735-8651","authenticated-orcid":false,"given":"Pieternella J.","family":"Lugtenburg","sequence":"additional","affiliation":[{"name":"On behalf of the Lunenburg Lymphoma Phase I\/II Consortium-HOVON\/LLPC, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2847"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002056"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.335"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.102625"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00430-6"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00889-8"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0177"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2027612"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016945"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.12.013"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30225-4"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30120-4"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00139-X"},{"key":"b22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3648"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00931"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03175"},{"key":"b25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7500"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00072-2"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.22.01725","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T18:00:33Z","timestamp":1681754433000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.22.01725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,4,20]]}},"alternative-id":["10.1200\/JCO.22.01725"],"URL":"https:\/\/doi.org\/10.1200\/jco.22.01725","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"2022-07-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}